A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab

BACKGROUND: Psoriasis is a chronic inflammatory skin condition that impacts quality of life and requires long-term treatment and effective symptom management. Interleukin-23 (IL-23) has emerged as a key player in the pathogenesis of psoriasis and tildrakizumab and guselkumab are both immunomodulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Du Jardin, Kristian Garn, Hurtado Lopez, Pepi, Lange, Mette, McCool, Rachael, Maeso Naval, Silvia, Quickert, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2020
Materias:
Dermatological Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398610/
https://www.ncbi.nlm.nih.gov/pubmed/32766377
http://dx.doi.org/10.36469/jheor.2020.13671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398610/
https://www.ncbi.nlm.nih.gov/pubmed/32766377
http://dx.doi.org/10.36469/jheor.2020.13671

Ejemplares similares